Compare · APTO vs GILD
APTO vs GILD
Side-by-side comparison of Aptose Biosciences Inc. (APTO) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APTO and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD carries a market cap of $208.48B.
- GILD has hit the wire 17 times in the past 4 weeks while APTO has been quiet.
- GILD has more recent analyst coverage (25 ratings vs 2 for APTO).
- Company
- Aptose Biosciences Inc.
- Gilead Sciences Inc.
- Price
- -
- -
- Market cap
- -
- $208.48B
- 1M return
- -
- +6.75%
- 1Y return
- -
- +35.43%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- News (4w)
- 0
- 17
- Recent ratings
- 2
- 25
Aptose Biosciences Inc.
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806 and CG-806, which are in Phase 1a/b clinical trial for the treatment of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed/refractory acute myeloid leukemia. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest APTO
- Aptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
- Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial
- Aptose Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Aptose Announces Auditor Not Standing for Re-Appointment
- Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
- SEC Form PRER14A filed by Aptose Biosciences Inc.
- SEC Form 8-K filed by Aptose Biosciences Inc.
- SEC Form PRE 14A filed by Aptose Biosciences Inc.
- SEC Form 8-K filed by Aptose Biosciences Inc.
- Aptose Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest GILD
- A Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year End
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M sold $557,810 worth of shares (3,399 units at $164.11) as part of a pre-agreed trading plan, decreasing direct ownership by 39% to 5,360 units (SEC Form 4)
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
- Chairman & CEO O'Day Daniel Patrick exercised 112,429 shares at a strike of $72.34 and sold $19,693,439 worth of shares (112,429 units at $175.16) as part of a pre-agreed trading plan (SEC Form 4)
- New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention
- SEC Form 13F-HR filed by Gilead Sciences Inc.
- Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)
- Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story
- Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
- Chairman & CEO O'Day Daniel Patrick exercised 15,881 shares at a strike of $72.34 and sold $5,329,178 worth of shares (30,881 units at $172.57) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 551,683 units (SEC Form 4)